



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile



Last updated: February 1, 2024

Preliminary Congress Program (last updated February 1, 2024)

THURSDAY, MARCH 21, 2024

16:00 – 18:00 | Registration at W SANTIAGO

FRIDAY, MARCH 22, 2024

07:30 – 17:00 | Registration at W SANTIAGO

FRI | 08:30 – 09:15 | Opening Ceremony

Welcome by the Congress Presidents and Program Overview

➤ *Horacio Amaral & Vasko Kramer – also in the name of Richard P. Baum and Frank Rösch*

FRI | 09:15 – 10:00 | Opening Lecture

➤ „Searching for our cosmic origins - A decade of molecular spectroscopy with ALMA“
Sergio Martin (ALMA Observatory)

FRI | 10:00 – 10.30 | COFFEE BREAK. VISIT OF EXHIBITION.

FRI | 10:30 – 11:15 | Session I – Radiotheranostics Global Access: Discussion with Patients and Experts – Supported by ICPO and Oncidium foundations

➤ *"Building hope: navigating through the challenges and barriers to treatment access "*
Moderator: Dr. Cristiana Gameiro, Oncidium foundation Advisor

FRI | 11:15 – 12:00 | Session II – Healthcare System Readiness for RLT

➤ *"The potential of RLT in cancer care in the next 10 years; call to action for Healthcare Systems Readiness: A Multi-stakeholder panel discussion around key barriers and about how to tackle the increasing number of patients eligible for RLT"*
Moderator: Prof. Dr. Richard Baum, ICPO / Curanosticum

FRI | 12:00 – 13.30 | LUNCH BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile

Last updated: February 1, 2024

FRI | 13:30 – 15:00 | Session III – Neuroendocrine Tumor Session

Chairpersons

t.b.a.

- ➔ Giovanni Paganelli (Italy) – to be confirmed
20 YEARS' EXPERIENCE WITH 177LU DOTATATE: FROM "ONE FITS ALL CONCEPT" TO A PERSONALIZED PPRT IN NEUROENDOCRINE TUMORS
- ➔ Helen Nadel (Stanford, USA)
PEDIATRIC THERANOSTICS: A BLUEPRINT FOR THE FUTURE
- ➔ Susanne Kossatz (TU Munich, Germany)
SPECIFIC BINDING OF SSTR2-TARGETING PPRT AGONISTS AND ANTAGONISTS TO HUMAN BONE MARROW STEM CELLS PROVIDE INSIGHTS INTO THEIR DISTINCT HEMATOTOXICITY PROFILES
- ➔ Ebrahim Delpassant (RadioMedix / Excel Diagnostics, USA)
LATEST UPDATES IN TARGETED ALPHA THERAPY (TAT) USING 212PB-DOTAMTATE FOR THE TREATMENT OF METASTATIC SSTR-EXPRESSING NEUROENDOCRINE TUMORS, IN PPRT NAÏVE AND PROGRESSED PATIENTS
- ➔ Lukas Greifenstein (Curanosticum, Germany)
SSTR2 ANTAGONISTS FOR DIAGNOSIS AND THERAPY OF NEUROENDOCRINE TUMORS - FROM INSTANT KIT-TYPE ATTEMPTS TO ALPHA THERAPY
- ➔ Thomas Günter (UCSF Stanford, USA)
DEVELOPMENTS TOWARDS THE CLINICAL TRANSLATION OF CCK-R2 LIGANDS FOR IMAGING AND THERAPY OF VARIOUS CANCERS

FRI | 15:00 – 15:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

FRI | 15:30 – 17:45 | Session IV – Prostate Cancer Session

Chairpersons

t.b.a.

- ➔ Matthias Eiber (Technische Universität München, Germany)
PROSTATE CANCER & PSMA-TARGETED THERANOSTICS
- ➔ Oliver Sartor (Mayo Clinic, USA)
PSMA LU177: RANDOMIZED TRIALS OVERVIEW
- ➔ Jae Min Jeong (South Korea)
NEW PSMA THERANOSTICS
- ➔ Mike Sathekge (University of Pretoria, South Africa)
225AC-PSMA RLT OF ADVANCED PROSTATE CANCER
- ➔ Chandrasekhar Bal (AIIMS, New Delhi, India)
225AC-PSMA-617 ALPHA THERAPY: CURRENT STATUS IN TREATING AGGRESSIVE PROSTATE CANCER



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile



Last updated: February 1, 2024

- ➔ Eleni Gourni (Inselspital Bern, Switzerland)
[177LU]LU-LF1: A GASTRIN RELEASING PEPTIDE RECEPTOR RADIOANTAGONIST WITH GREAT PROMISE IN ADVANCING PROSTATE CANCER TREATMENT
- ➔ Andrei Iagaru (Stanford, USA)
A DECADE OF GRPR PET IMAGING - WHERE ARE WE AND WHERE ARE WE GOING”?
- ➔ Michael Hofman (PeterMac, Australia)
PROSTIC24 RECAP

FRI | 20:00 – 24:00 | FESTIVE EVENING* INCLUDING AWARD CEREMONY

Award Ceremony

- ➔ Saul Hertz Young Investigator Award (presented by Barbara Hertz)
- ➔ Edwaldo E. Camargo Young Investigator Award (presented by Elba Etchebehere Camargo)
- ➔ Jorge Nicolini Young Investigator Award (presented by Mariano E. Nicolini)

**Must be booked additionally.*



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile

Last updated: February 1, 2024

SATURDAY, MARCH 23, 2024

SAT | 08:30 – 10:00 | Session V – Medical Physics & Instrumentation

Chairpersons

t.b.a.

- ➔ Simon Cherry (UC Davis, USA)
WHOLE-BODY PET/CT AND WHAT IT CAN CONTRIBUTE TO THE DEVELOPMENT OF NEW THERANOSTIC APPROACHES
- ➔ Thomas Beyer (University Vienna, Austria)
A FRAMEWORK TO ENGAGE THE IMAGING COMMUNITY IN ADVANCING TOTAL-BODY PET
- ➔ Kuangyu Shi (University of Bern, Switzerland)
KNOWLEDGE-GUIDED ARTIFICIAL INTELLIGENCE FOR PERSONALIZED NUCLEAR MEDICINE THERANOSTICS
- ➔ Bryan P. Bednarz (Univ. Wisconsin, USA)
ALPHA-PARTICLE DOSIMETRY
- ➔ Harshad Kulkarni (BAMF, USA)
TRANSFORMING THERANOSTICS: INTEGRATION OF AI AND MACHINE LEARNING FOR PRECISION MOLECULAR IMAGING

Panel Discussion

Moderation: Thomas Beyer

SAT | 10:00-10:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

SAT | 10:30 – 13:30 | Presentations by the Industry

SAT | 13:30 – 15:00 | Session VI – Novel Targets & Chemistry

Chairpersons

t.b.a.

- ➔ Jakub Simecek (Trimt, Germany)
RECENT PROGRESS OF INTEGRIN-TARGETED THERANOSTICS
- ➔ Andreas Buck (University Hospital Würzburg, Germany) – to be confirmed
IMAGING OF CXCR4 EXPRESSION IN PATIENTS WITH HEMATOLOGIC NEOPLASMS



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile



Last updated: February 1, 2024

- ➔ Baljinder Singh (Chandigarh, India)
EMERGING 68GA-PENTIXAFOR PET/CT APPLICATIONS FOR TARGETING CXCR4 RECEPTORS IN HUMAN CANCERS- AN INDIAN EXPERIENCE
- ➔ Shawn Chen (LNC, Singapore)
177LU-LNC1011: STRIKING THE BALANCE OF CIRCULATION HALF-LIFE AND TUMOR ACCUMULATION FOR PROSTATE CANCER THERAPY
- ➔ Matthias Herth (University of Copenhagen, Denmark)
211AT-PSMA FOR ALPHA-RLT OF PROSTATE CANCER
- ➔ Wolfgang Weber (TU Munich, Germany)
NOVEL TARGETS BEYOND FAPI: HSP70, GAL3

SAT | 15:00 – 15.30 | LUNCH BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

SAT | 15:30 – 16:20 | Session VII – TME Diagnostics

Chairpersons

t.b.a.

- ➔ Pieter van der Veken (University of Antwerp, Belgium)
DRUGLIKE, 18F-LABELED PET TRACERS TARGETING FIBROBLAST ACTIVATION PROTEIN (FAP)
- ➔ Frederik Giesel (Heinrich Heine University Düsseldorf, Germany) – virtual
OVERVIEW OF TODAY'S CLINICAL APPLICATIONS AND PERSPECTIVES
- ➔ Sherly Mosessian (Sofie Bioscience, USA) & Paul Evans (GE, USA)
FAP – ADVANCEMENTS IN DIAGNOSTICS
- ➔ Tadashi Watabe (Osaka University, Japan) – to be confirmed
FAP DIAGNOSTICS – CRITICAL VIEW ON CLINICAL DEVELOPMENT
- ➔

SAT | 16:20 – 18:00 | Session VIII – TME Therapeutics

Chairpersons

t.b.a.

- ➔ Richard P. Baum (Curanosticum & ICPO, Germany)
CLINICAL APPLICATIONS AND PERSPECTIVES OF 3BP-3940
- ➔ Marcel Martin (University Mainz, Germany)
FAP-DIMERS-CHEMISTRY AND PRECLINICAL EVALUATION
- ➔ Sanjana Ballal (AIIMS, New Delhi, India)
ASSESSING THE LONG-TERM IMPACT OF FAP DIMER THERAPY IN CANCER TREATMENT



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile



Last updated: February 1, 2024

- ➔ John Babich (Ratio Therapeutics, USA)
NEXT GENERATION ⁶⁴CU- AND ²²⁵AC-LABELLED RADIOLIGANDS FOR FAP-TARGETED THERAPY
- ➔ Jacqueline Mock (Philogen, USA) – virtual
NOVEL FAP-TARGETING SMALL MOLECULE RADIO-CONJUGATES WITH HIGH AND PROLONGED TUMOUR UPTAKE
- ➔ Jingjing Zhang (University of Singapore, Singapore)
RADIODIAGNOSTICS WITH DUAL TARGETING PROBE ⁶⁸GA-/¹⁸F-/¹⁷⁷LU-FAPI-RGD IN DIVERSE SOLID TUMORS

Panel Discussion

Moderation: Frank Rösch



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile

Last updated: February 1, 2024

SUNDAY, MARCH 24, 2024

SUN | 08:00 – 10:00 | Session IX – Current State of Isotope Production

Chairpersons

t.b.a.

- ➔ Cathy Cutler (Brookhaven National Laboratory, USA)
CURRENT STATUS OF DOE ISOTOPE PRODUCTION PROGRAM FOR THERANOSTIC RADIONUCLIDES
- ➔ Valery Radchenko (Triumpf, University of British Columbia, Canada)
CURRENT STATUS OF CANADIAN ISOTOPE PRODUCTION PROGRAM FOR THERANOSTIC RADIONUCLIDES
- ➔ Jean-Francois Gestin (COST, NOAR, France)
AT-211: RECENT PROGRESS IN ISOTOPE PRODUCTION, PHARMACEUTICAL CHEMISTRY, CLINICAL TRANSLATION
- ➔ Michael Schultz (Perspective Therapeutics, USA)
PB203 IMAGE GUIDED PB212 ALPHA PARTICLE THERAPY FOR CANCER - A GLOBAL SOLUTION FOR MULTIPLE INDICATIONS
- ➔ Jason Lewis (MSKCC, USA)
CU-64/67: RECENT PROGRESS IN ISOTOPE PRODUCTION, PHARMACEUTICAL CHEMISTRY, CLINICAL TRANSLATION
- ➔ Suzanne Lapi (University of Alabama, USA)
PB-203/212 & SC-44/47: RECENT PROGRESS IN ISOTOPE PRODUCTION, PHARMACEUTICAL CHEMISTRY, CLINICAL TRANSLATION
- ➔ Eduardo Aluicio Sarduy (Wisconsin Cyclotron Lab, USA)
Y-86/90 & SC-44: RECENT PROGRESS IN ISOTOPE PRODUCTION, PHARMACEUTICAL CHEMISTRY, CLINICAL TRANSLATION

SUN | 10:00 – 10:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

SUN | 10:30 – 13:30 | Presentations by the Industry

SUN | 13:30 – 15:00 | Session X – Novel Indication, Concepts & Genetics

Chairperson

t.b.a.

- ➔ Rodney Hicks (Australia)
WHAT DOESN'T KILL ME MAKES ME STRONG!



March 22-24, 2024

7th Theranostics World Congress

Santiago, Chile



Last updated: February 1, 2024

- ➔ Andreas Kjaer (University of Copenhagen, Denmark)
UPAR THERANOSTICS: TARGETING THE INVASIVE PHENOTYPE
- ➔ Jean Pierre Pouget (INSERM, Montpellier, France)
IMMUNOSTIMULATORY EFFECTS OF TARGETED RADIOLIGAND THERAPY
- ➔ Jolanta Kunikowska (Nuclear Medicine Department, Medical University of Warsaw, Poland)
RADIONUCLIDE TARGETED TREATMENT FOR GLIOMA: SUBSTANCE-P AND PSMA
- ➔ Ralph Wirtz (Stratifyer, Germany)
PARADIGM SHIFT IN BLADDER CANCER TREATMENT: THERANOSTIC INCUBATOR CONCEPT TO TREAT CHEMOTHERAPY RESISTANT MUSCLE-INVASIVE BLADDER CANCER
- ➔ Masha Maharaj (South Africa)
BRCA GERMLINE POSITIVE VS SOMATIC BRCA AND THE IMPACT ON PROSTATE CANCER
- ➔ Julie Conzanzo (INSERM, Montpellier, France) – to be confirmed
NANOPARTICLE ENHANCED RADIOLIGAND THERAPY (NERT)

SUN | 15:00 – 15:30 | COFFEE BREAK. E-POSTER VIEWING. VISIT OF EXHIBITION.

SUN | 15:30 – 17:00 | Session XI – Combination Therapies

Chairpersons

t.b.a.

- ➔ Michael Hofman (PeterMac, Australia)
THERANOSTICS 2.0: EMBRACING THE POWER OF PSMA COMBINATIONS
- ➔ Patrick Flamen (Hôpital Universitaire de Bruxelles, Belgium)
COMBINING RADIOLIGAND THERAPY AND IMMUNE CHECKPOINT INHIBITORS: PRECLINICAL RATIONALE AND ONGOING CLINICAL TRIALS
- ➔ Michael Bachmann (FZ Dresden-Rossendorf, Germany)
COMBINATORIAL THERANOSTIC TARGETING OF TUMORS AND THE TUMOR MICROENVIRONMENT
- ➔ Bernd Krause (University Hospital Rostock, Germany) – virtual
GRPR THERANOSTICS IN PROSTATE CANCER
- ➔ Vikas Prasad (Mallinkrodt Institute of Radiology, USA)
HOW TO BEST COMBINE IMMUNOTHERAPY WITH RADIOPHARMACEUTICAL THERAPY
- ➔ Andrew Scott (Olivia Newton John Cancer Research Institute, Australia)
ENHANCING THE EFFICACY OF THERANOSTICS WITH DNA DAMAGE REPAIR INHIBITORS

SUN | 17:00 – 17:30 | CLOSING CEREMONY

Vasko Kramer / Horacio Amaral / Richard P. Baum / Frank Rösch